Clinical trials: Erectile Dysfunction
Erectile Dysfunction
Radial Shockwave Therapy for Erectile Dysfunction
Objective: To evaluate the efficacy and safety of radial shock waves for the treatment of erectile dysfunction [ED]. Patients and methods: Randomized, double-blind clinical trial.
- Trial name
- NCT03596047
- Testing
- Radial wave therapy
- Where
- Colombia
- Volunteers
- 80 people
- Sponsor
- Boston Medical Group
Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction
Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered
The purpose of this study is to evaluate pharmacokinetics, safety and tolerability profile of BZ371A topically administered in healthy patients.
- Conditions
- Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction, Prostate Cancer, Radical Prostatectomy
- Trial name
- NCT05332340
- Testing
- BZ371A
- Where
- Brazil
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Biozeus Biopharmaceutical S.A.
Heart Failure, Heart Failure, Systolic
COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
The purpose of this study was to determine the effect of sacubitril/valsartan (LCZ696) vs. Enalapril on improvement in erectile function and ability in male patients with chronic heart failure with reduced ejection fraction and…
- Conditions
- Heart Failure, Heart Failure, Systolic, Erectile Dysfunction
- Trial name
- CONFIDENCE-HF (NCT03917459)
- Testing
- LCZ696, Enalapril
- Where
- 13 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Erectile Dysfunction
Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction
An open-label investigation using MED3000 gel or tadalafil (5 mg) tablets in the treatment of erectile dysfunction in patients from 22 to 70 years of age. Each patients will be expected to participate for up to 30 weeks.
- Trial name
- NCT04984993
- Testing
- MED3000 (Male), Tadalafil 5mg (Male), MED3000 (Female)
- Where
- 18 sites in United States, Bulgaria and 2 more
- Volunteers
- 116 people
- Sponsor
- Futura Medical Developments Ltd.
Erectile Dysfunction, Cardiovascular Diseases
Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor
Erectile dysfunction (ED) has been identified as an independent risk factor for existing cardiovascular disease, preceding a major cardiovascular event by an average of about 5 years.
- Conditions
- Erectile Dysfunction, Cardiovascular Diseases, Male Urogenital Diseases
- Trial name
- NCT01150903
- Testing
- no intervention
- Volunteers
- 98,832 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Erectile Dysfunction
A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction.
A multicenter open label study to assess the efficacy of sildenafil rapid dose titration to 100 mg in men with erectile dysfunction, based on the Erectile Function (EF) domain score of the International Index of Erectile Function…
- Trial name
- NCT00468650
- Testing
- sildenafil citrate
- Where
- 9 sites in Mexico
- Volunteers
- 117 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Erectile Dysfunction, Impotence
PROPPER Prospective Registry of Outcomes With Penile Prosthesis
The purpose of this observational registry is to collect and better understand "real-world" outcomes for men undergoing penile implant surgery to treat erectile dysfunction.
- Trial name
- PROPPER (NCT01383018)
- Testing
- AMS Penile Prosthesis Devices
- Where
- 11 sites in United States, Canada
- Volunteers
- 1,457 people
- Sponsor
- Boston Scientific Corporation
Impotence
Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied
Men's quality of life (QoL) is potentially affected by mild erectile dysfunction (ED) to the same extent as it is by moderate and severe ED.
- Trial name
- NCT00301262
- Testing
- Viagra (Sildenafil citrate)
- Where
- 26 sites in Canada
- Volunteers
- 183 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Erectile Dysfunction
A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate
The purpose of this study is to perform a relative bioavailability study between two formulations of sildenafil citrate.
- Trial name
- A1481272 (NCT00904748)
- Testing
- sildenafil citrate 100 mg CT, Viagra®
- Where
- Brazil
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Erectile Dysfunction
Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.
This study will evaluate if an orally disintegrating tablet of sildenafil will have similar pharmacokinetic properties when given with food and without food.
- Trial name
- NCT01254396
- Testing
- Sildenafil
- Where
- Singapore
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Erectile Dysfunction
Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)
This study is designed to evaluate the efficacy and safety of MED2005, a topically applied glyceryl trinitrate (GTN) gel administered to the penis of male subjects self-diagnosed with erectile dysfunction (ED) immediately before…
- Trial name
- NCT02495467
- Testing
- Glyceryl trinitrate
- Where
- United Kingdom
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Futura Medical Developments Ltd.
Erectile Dysfunction
A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction
The purpose of this study is to evaluate the safety and effectiveness of the study drug, taken once daily, known as tadalafil in Chinese participants with erectile dysfunction (ED).
- Trial name
- NCT02224846
- Testing
- Tadalafil
- Where
- 17 sites in China
- Volunteers
- 635 people
- Sponsor
- Eli Lilly and Company
Erectile Dysfunction
Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED
To evaluate the safety and efficacy of a single intracavernous injection of hMaxi K (8000 µg and 16000 µg) or placebo upon penile rigidity or erection in males with erectile dysfunction longer than six months that is attributable…
- Trial name
- NCT02713789
- Testing
- hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)
- Where
- Kuwait
- Volunteers
- 26 people
- Sponsor
- Urovant Sciences GmbH
Erectile Dysfunction
Evaluation of the 2005 AMS (American Medical System) IPP (Inflatable Penile Prosthesis)
The purpose of this study is to evaluate modifications to the AMS 700 Series pump, cylinders, reservoir and rear tip extender design, their impact on ease of use for the patient, and ease of implantation for the physician.
- Trial name
- NCT00636506
- Testing
- AMS 700 IPP with MS Pump
- Where
- 7 sites in United States
- Volunteers
- 76 people
- Sponsor
- American Medical Systems
Erectile Dysfunction
A Bioavailability Study of LY2452473 and Tadalafil
This study compares LY2452473 taken orally as a 5 milligram (mg) capsule at the same time as a 5 mg tadalafil tablet with three different combination tablets (LY900010) of 5 mg LY2452473 and 5 mg tadalafil taken orally.
- Trial name
- NCT01401543
- Testing
- LY2452473, Tadalafil, LY900010
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Erectile Dysfunction
A Study of LY900010 in Erectile Dysfunction
The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED) who incompletely respond to tadalafil alone.
- Trial name
- NCT01160289
- Testing
- LY2452473, tadalafil
- Where
- 36 sites in United States
- Volunteers
- 410 people
- Sponsor
- Eli Lilly and Company
Anterior Ischemic Optic Neuropathy
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.
- Trial name
- NCT00867815
- Testing
- Diagnostic procedures
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Benign Prostate Hyperplasia, Erectile Dysfunction
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
The purpose of this study is to see whether tadalafil can reduce the signs and symptoms in men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-Lower Urinary Tract Symptoms (BPH-LUTS) and improve their quality of…
- Trial name
- NCT01937871
- Testing
- 5 mg Tadalafil, 0.2 mg Tamsulosin
- Where
- 14 sites in China
- Volunteers
- 909 people
- Sponsor
- Eli Lilly and Company
Erectile Dysfunction
Study Evaluating the Effects of Avanafil on Semen Parameters
The purpose of this study is to determine whether avanafil will affect different aspects of sperm production.
- Trial name
- NCT01768676
- Testing
- avanafil
- Where
- 15 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Erectile Dysfunction, Metabolic Syndrome
Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome
This is a controlled, randomized, multi-center prospective study of vardenafil to determine efficacy on Erectile Dysfunction (ED), tolerability and safety in men with ED and Metabolic Syndrome.
- Trial name
- NCT00738400
- Testing
- Vardenafil (Levitra, BAY38-9456)
- Where
- 19 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Bayer